Intermittent Fasting in Multiple Sclerosis
Randomized Controlled Trial on Intermittent Fasting in Multiple Sclerosis
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Intermittent fasting
What it measured
Main measures
Leptin
12 weeks
Other measures (3)
Peripheral metabolic and inflammatory profiling
12 weeks
Anthropometric measure
12 weeks
Gut microbiota
12 weeks
Who could take part
Relapsing MS · 18 and over
Show the full criteria
Inclusion criteria
* Diagnosis of RRMS (2010 Mc Donald criteria). * EDSS \<6.0 and disease duration ≤ 15 years. * On an injectable therapy for MS, glatiramer acetate (GA) or beta-interferon (beta-IFN) for at least 3 months prior to the study and with no anticipated changes of the medication for the 12 week study duration. * Age ≥18 years. * BMI > 22 and \< 35 kg/m2 with stable weight in the 3 months prior to screening.
Exclusion criteria
* History of any chronic disease process (excluding MS) that could interfere with interpretation of results. * Diagnosis in the past of an eating disorder (anorexia, bulimia, or binge eating). * Relapsing at the time of enrollment. * On corticosteroid treatment (oral or intravenous) in the past month. Nasal corticosteroid treatments are allowed. * Diagnosis of diabetes or at time of OGTT (fasting glucose >126 mg/dl or > 200 mg/dl at 2 hours with a load of 75 g of glucose * History of food allergies or food intolerance that would interfere with the study. * History of antibiotic treatment within the past 3 months prior to enrollment * Use of anticoagulant drugs (like Warfarin or Coumadin) that need to monitor their intake of vegetables containing high levels of vitamin K. * Currently on a special diet and not willing to stop at least one month prior to enrollment * Currently taking omega 3/fish oil supplements and not willing to stop administration one month prior to enrollment * Currently pregnant or plan to become pregnant within 6 months * Current tobacco or e-cigarette smoker
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This is a randomized controlled trial that will test the effects of intermittent fasting (IF) in subjects with relapsing-remitting MS (RRMS). The goal of this clinical trial is to acquire objective evidence regarding whether an IF diet has beneficial effects in MS patients.Two dietary regimens, IF and western diet, will be compared in a randomized, controlled, single-blinded 12 week trial in RRMS patients. This is a single-center study.
Papers
Results
Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis.J Neurol Neurosurg Psychiatry · 2025
Results
Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimer's Disease.J Alzheimers Dis · 2023
Loading reviews and guidelines…
History
Started
Jan 2018
Main results due
Jan 2022
Finished
Jan 2022